Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Although this secondary analysis was not prospectively registered, both the exposure and outcomes were predefined based on those reported in the original trial, and the research question was based on a priori biological rationale
Dosing Strategy for HIV-Associated Neuropathy: Dose: 1,500-3,000 mg/day in divided doses Duration: Minimum 24 weeks
et al., 2025) (Figure 5)
67 PEG-loxenatide, Chinas first long-acting GLP-RA product, was approved for marketing in China in May 2019
(3) Ionescu M, Frohman LA
US$ 26.50
US$ 23.08
US$ 27.97
US$ 21.56
US$ 24.04
